Key result
Mechanical thrombectomy in-hospital stroke mortality linked to ~17% lower odds per year from 2008-2012.
Why the study?
Mechanical thrombectomy for acute ischemic stroke has been increasingly used while its therapeutic benefit remains debated, necessitating examination of national mortality trends.
Observational (n=16,307)
Yes
Odds Ratio: 0.832
Absolute Event Rate: 16.1% vs 25.4%
p-value: p=<0.001
Mortality after mechanical thrombectomy declined over time; supports evolving care patterns but leaves open causal drivers for prospective study.
BACKGROUND AND PURPOSE: Mechanical thrombectomy (MT) for the treatment of acute ischemic stroke has been growing in popularity while the therapeutic benefit of MT has been increasingly debated. Our objective was to examine national trends in mortality following MT. METHODS: We analyzed the National Inpatient Sample (2012) and the Nationwide Inpatient Sample (2008-2011) for patients with a primary diagnosis of acute ischemic stroke that received MT. Temporal trends in mortality were examined using Spearman's rank correlation. To account for confounding factors, mortality was further analyzed in binary logistic regression. RESULTS: Hospitals performing MT comprised 8% of all hospitals treating ischemic stroke. The percentage of stroke cases treated with MT increased from 0.6% of cases in 2008 to 1.1% in 2012, totaling 16 307 MT cases in a 5 year period. Inhospital mortality decreased over the study period from 25.4% in 2008 to 16.1% in 2012 (r=-0.081, p<0.001). This finding was supported by regression analysis as each incremental year reduced the odds of mortality by 20% (OR=0.832, p<0.001). Administration of recombinant tissue plasminogen activator was associated with a decrease in the odds of mortality (OR=0.805, p<0.001). CONCLUSIONS: Utilization of MT represents a small percentage of stroke cases, although the trend is increasing. Mortality following MT has been showing a steady decline over the past 5 years. This may be a result of a learning curve, improved patient selection, and/or device improvements. Randomized trials remain essential to evaluate the potential benefit of endovascular devices and identify the most appropriate patients.
No takes yet. Share an insight, caveat, or question.
Villwock et al. (2015) conducted an observational in Acute ischemic stroke (n=16,307). Mechanical thrombectomy vs. Earlier treatment year (2008 vs 2012) was evaluated on In-hospital mortality (OR 0.832, p=<0.001). In-hospital mortality following mechanical thrombectomy for acute ischemic stroke decreased from 25.4% in 2008 to 16.1% in 2012, with each incremental year reducing mortality odds by 20% (OR 0.832).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: